By Bhanvi Satija and Christy Santhosh (Reuters) -Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do not inform patients of the ...

Novo sells semaglutide as Ozempic and Rybelsus for diabetes and as Wegovy for obesity. In price talks, CMS will treat the different forms as a single product.

Half of the websites (49.4%) failed to mention risks including adverse effects, warnings and precautions, and ...

Websites selling compounded versions of popular weight-loss drugs from Novo Nordisk and Eli Lilly to U.S. consumers often do ...

The Biden administration announced Friday that Ozempic, Wegovy and 13 additional drugs will now be covered under Medicare ...

Pharmaceutical giants Eli Lilly and Novo Nordisk, makers of Zepbound and Wegovy, respectively, have filed lawsuits against medical spas, weight-loss clinics, and compounding pharmacies they accuse of ...

A new request by Ozempic manufacturer Novo Nordisk could limit the availability of a type of GLP-1—semaglutides—to local ...

Kwame Raoul’s office sent cease and desist letters to five unnamed medical spas in the Chicago area that were allegedly ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

On December 19, 2024, the U.S. Food and Drug Administration (FDA) issued a declaratory order determining that the shortage of diabetes and ...

Novo specifically requested semaglutide be added to the FDA’s Demonstrable Difficulties for Compounding lists, citing complexities around formulations, delivery mechanisms, dosage forms ...

Tirzepatide and semaglutide both belong to a class of drugs known as GLP-1s. Compounding pharmacies have been producing copycat versions of the drugs while they have been in short supply.